Boothbay Fund Management LLC Sells 70,000 Shares of Drugs Made In America Acquisition Corp. $DMAA

Boothbay Fund Management LLC lessened its holdings in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 12.3% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 500,000 shares of the company’s stock after selling 70,000 shares during the quarter. Boothbay Fund Management LLC owned approximately 1.71% of Drugs Made In America Acquisition worth $5,135,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Karpus Management Inc. boosted its position in Drugs Made In America Acquisition by 18.1% in the 2nd quarter. Karpus Management Inc. now owns 2,744,109 shares of the company’s stock valued at $27,990,000 after buying an additional 420,075 shares during the period. Wolverine Asset Management LLC raised its stake in shares of Drugs Made In America Acquisition by 22.2% during the third quarter. Wolverine Asset Management LLC now owns 1,249,128 shares of the company’s stock valued at $12,829,000 after acquiring an additional 227,222 shares in the last quarter. Radcliffe Capital Management L.P. boosted its holdings in shares of Drugs Made In America Acquisition by 316.7% in the third quarter. Radcliffe Capital Management L.P. now owns 528,100 shares of the company’s stock valued at $5,424,000 after purchasing an additional 401,378 shares during the period. Context Capital Management LLC purchased a new stake in shares of Drugs Made In America Acquisition in the third quarter valued at approximately $2,568,000. Finally, Shaolin Capital Management LLC grew its stake in Drugs Made In America Acquisition by 50.0% in the third quarter. Shaolin Capital Management LLC now owns 150,000 shares of the company’s stock worth $1,540,000 after purchasing an additional 50,000 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Drugs Made In America Acquisition Price Performance

Shares of DMAA stock opened at $10.47 on Monday. The stock’s 50-day moving average is $10.43 and its 200 day moving average is $10.36. Drugs Made In America Acquisition Corp. has a 1-year low of $9.98 and a 1-year high of $10.49.

Drugs Made In America Acquisition Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.